Parse Biosciences. a Seattle biotech startup developing single cell sequencing products used by more than 1,000 labs worldwide, raised $50 million as part of a Series C equity round and a debt facility. Read More GeekWire
Parse Biosciences. a Seattle biotech startup developing single cell sequencing products used by more than 1,000 labs worldwide, raised $50 million as part of a Series C equity round and a debt facility.
The company, previously known as Split Biosciences, spun out of the University of Washington in 2018 and launched in 2021.
Parse is led by CEO/co-founder Alex Rosenberg, and CTO/co-founder Charlie Roco.
Soleus Capital led the Series C round, which included participation from Bioeconomy Capital, Janus Henderson Investors, Marshall Wace, Sahsen Ventures, and Saras Capital. Horizon Technology Finance Corporation (HRZN) provided the debt facility.
